Beyond Hormone Therapy: What's Next for Advanced Prostate Cancer

Was this helpful? (1)
ADVERTISEMENT
PHYSICIAN CONTRIBUTOR Products for Sensitive Skin promo image

6 Products for Sensitive Skin

Looking for ways to soothe sensitive skin? Here are six of the best skin care products.
Male doctor with male patient

For many men, treatment with surgery, chemotherapy, or radiation stops or slows down prostate cancer. Up to 40 percent of the time, however, prostate cancer progresses despite treatment. And some men are unable to have these treatments because of other medical conditions, are diagnosed with prostate cancer at an advanced stage, or have cancer that comes back after treatment.

Doctors have found treating these cases of cancer difficult. However, new treatments are emerging for men with a form of the disease known as castration-resistant prostate cancer. Research has revealed more about how this condition develops, leading to breakthroughs that are helping treat it.

Targeting Hormones to Slow Cancer

If you can't have surgery, chemotherapy, or radiation treatments—or if these treatments don't work for you—your doctor will probably recommend hormone therapy. Hormone therapy prevents testosterone and other hormones called androgens from reaching prostate cancer cells and fueling their growth.

There are two types of hormone therapy: surgical and chemical. Both are effective in reducing hormone levels. Surgical castration involves removal of the testicles. If you choose chemical castration, you'll take medications called luteinizing hormone-releasing hormone (LHRH) analogs. LHRH analogs are either injected or implanted under the skin.

When Cancer Fights Back

Hormone therapy will likely shrink your tumors, ease your symptoms, and help you live longer. However, these treatments do not cure prostate cancer.

After a while—typically one to three years after beginning hormone therapy—your cancer will become resistant to this treatment. Although your androgen levels remain low, your doctor will detect an increase in your levels of prostate-specific antigen (PSA), a chemical in your blood that identifies prostate cancer. Or, he or she may see new tumors on an imaging test.

Doctors aren't sure why the cancer becomes resistant to hormone therapy. They believe cancer cells mutate so they no longer require androgens to grow. When that happens, you're said to have castration-resistant prostate cancer.

New Therapies Offer Hope

Treatment for this type of cancer is rapidly changing. Now, men have many more options than ever before. Your doctor may recommend:

  • Docetaxel (Docefrez, Taxetere) and Cabazitaxel (Jevtana). In many cases, prostate cancer cells pump out anticancer drugs before they can be effective. These taxane chemotherapy agents seem to sneak past these defenses. They are given as an infusion, which means a doctor or nurse injects this medication into your vein, usually for an hour every three weeks. You'll take a steroid called prednisone at the same time. Prednisone helps treat your cancer symptoms by replacing other hormones your body normally produces naturally. 

  • Abiraterone acetate (Zytiga) and Enzalutamide (Xtandi). Most hormone therapy stops your testicles from producing androgens. However, other tissues—including prostate cancer cells themselves—can also make small amounts of testosterone. These drugs, which come as a tablet and is also taken with prednisone, stops other cells from producing cancer-fueling hormones by blocking an enzyme called CYP17.

  • Sipuleucel-T (Provenge). This injection is actually a vaccine. Unlike other vaccines, which prevent a disease, it treats prostate cancer. Sipuleucel-T works by stimulating your immune system to attack and kill cancer cells.

In clinical trials, all these treatments helped men with castration-resistant prostate cancer live longer, better lives. Several other new therapies are showing promise and will likely be available soon.
Over time, doctors hope new research will help them determine which treatment will work best for which patient. Cancer therapy can then be more effective for each individual.


Key Takeaways

  • Hormone therapy is often recommended for prostate cancer patients who can't have other treatments, such as chemotherapy, or if those other treatments don't work for them.

  • Sometimes prostate cancer becomes resistant to hormone therapy. It's then called castration-resistant prostate cancer.

  • More treatments for castration-resistant prostate cancer are becoming available, including docetaxel, cabazitaxel, abiraterone acetate, enzalutamide, and sipuleucel-T. 


Was this helpful? (1)
Medical Reviewers: William C. Lloyd III, MD, FACS Last Review Date: Apr 19, 2017

© 2018 Healthgrades Operating Company, Inc. All rights reserved. May not be reproduced or reprinted without permission from Healthgrades Operating Company, Inc. Use of this information is governed by the Healthgrades User Agreement.

View Sources

Medical References

  1. Emerging Targeted Therapies for Castration-Resistant Prostate Cancer. V. Adamo et al. Frontiers in Cancer Endocrinology. Vol. 3, no. 73.
  2. Management of Metastatic Castration-Resistant Prostate Cancer: Recent Advances. D. Mukherji et al. Drugs. Vol. 72, no. 8, pp. 1011-28.
  3. Metastatic Castrate-Resistant Prostate Cancer: Dawn of a New Age of Management. S. Masson and A. Bahl. BJU International. epub ahead of print.
  4. New Treatment Options for Patients with Metastatic Castration-Resistant Prostate Cancer. C. S. Higano. Cancer Treatment Reviews. Vol. 38, no. 5, pp. 340-5.
  5. Novel Therapeutics for the Management of Castration-Resistant Prostate Cancer (CRPC). D. J. Lee et al. BJU International. Vol. 109, no. 7, pp. 968-85.
  6. Novel Treatments for Castration-Resistant Prostate Cancer. C.N. Sternberg. European Journal of Cancer. Vol. 47, suppl. 3, pp. S195-9.
  7. Therapeutic Options for Advanced Prostate Cancer: 2011 Update. A. Omlin and J.S. de Bono. Current Urology Reports. Vol. 13, no. 2, pp. 170-8.
  8. Urologists and Oncologists: Adapting to a New Treatment Paradigm in Castration-Resistant Prostate Cancer (CRPC). A. O. Sartor and J. M. Fitzpatrick. BJU International. epub ahead of print.
  9. Prostate Cancer Treatment (PDQ®): Patient Version. National Cancer Institute. http://cancer.gov/cancertopics/pdq/treatment/prostate/Patient/page1/AllPages/Print
  10. New Drug Benefits Patients with Advanced Prostate Cancer. National Cancer Institute. http://cancer.gov/clinicaltrials/results/cabazitaxel0310
  11. Prostate Cancer. American Cancer Society. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/index
  12. What’s New in Prostate Cancer Research and Treatment? American Cancer Society. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-new-research
  13. Infusion FAQs. National Home Infusion Association. http://www.nhia.org/faqs.cfm#faq1
  14. Prednisone. U.S. National Library of Medicine. National Institutes of Health. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601102.html
  15. Cabazitaxel Injection. U.S. National Library of Medicine. National Institutes of Health. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a611009.html
  16. Sipuleucel-T Injection. U.S. National Library of Medicine. National Institutes of Health. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a611025.html
  17. Abiraterone. U.S. National Library of Medicine. National Institutes of Health. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a611046.html

You Might Also Like